贝伐在卵巢癌研究.pptVIP

* * * * * * * * * * * In this slide, we see the academic (MRC) analysis of PFS. This is very similar to the regulatory analysis. The striking point is the crossing of the curves at around 23 months (11 months after the last dose of bevacizumab). As Dr Tim Perren explained at ESMO, this presents a challenge when interpreting the statistics. The crossing implies that the hazards are not proportional. As the assumption that hazards are proportional is not true, the hazard ratio and the median may not be the most appropriate way of describing the differences between the two treatment regimens. * *